Evolus Decision in Botox Battle Delayed by U.S. Trade Agency

The U.S. International Trade Commission delayed issuing a final decision in a trade secrets case that could determine if Evolus can continue selling Jeuveau, its rival to the Botox wrinkle treatment.

• The Washington agency said it will issue its decision Dec. 16; a decision had been scheduled for today
  • NOTE: Delays are fairly common at the agency
• AbbVie’s Allergan and its South Korea partner Medytox claim that Jeuveau was developed with stolen trade secrets, and a trade judge backed some of those allegations in findings released in July
• Evolus and its partner, Daewoong Pharmaceutical, deny the charges and ...